scholarly journals Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia

2021 ◽  
Vol 195 (1) ◽  
pp. 95-107
Author(s):  
Renata Bezdekova ◽  
Tomas Jelinek ◽  
Romana Kralova ◽  
Martin Stork ◽  
Petra Polackova ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Plasma Cell ◽  
Clinical Characteristics ◽  
Plasma Cells ◽  
Cell Leukaemia ◽  
Plasma Cell Leukaemia ◽  
Secondary Plasma

scholarly journals Secondary plasma cell leukaemia treated with single agent venetoclax

2020 ◽  
Vol 190 (4) ◽  
Author(s):  
Siobhan V. Glavey ◽  
Lyndsey Flanagan ◽  
Rachel Bleach ◽  
Claire Kelly ◽  
John Quinn ◽  
...  
Keyword(s):  
Plasma Cell ◽  
Single Agent ◽  
Cell Leukaemia ◽  
Plasma Cell Leukaemia ◽  
Secondary Plasma

2 Translocations, t(11;14) and t(l;6), in a Patient with Plasma Cell Leukaemia and 2 Populations of Plasma Cells

2009 ◽  
Vol 24 (1) ◽  
pp. 42-46 ◽  
Author(s):  
Gösta Gahrton ◽  
Lore Zech ◽  
Kenneth Nillsson ◽  
Berit Lönnqvist ◽  
Anders Carlström
Keyword(s):  
Plasma Cell ◽  
Plasma Cells ◽  
Cell Leukaemia ◽  
Plasma Cell Leukaemia

Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia

2016 ◽  
Vol 40 ◽  
pp. 30-32 ◽  
Author(s):  
Giuseppe Mele ◽  
Maria Rosaria Coppi ◽  
Gianluca Guaragna ◽  
Alessandro Spina ◽  
Angela Melpignano
Keyword(s):  
Plasma Cell ◽  
Low Dose ◽  
Cell Leukaemia ◽  
Plasma Cell Leukaemia ◽  
Secondary Plasma

Rapid and Excellent Response to Hyper CVAD, Particularly with Thalidomide, in Plasma Cell Leukaemia and Long Term Remissions Following Allogeneic Stem Cell Transplantation.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4963-4963 ◽  
Author(s):  
Vidhya Murthy ◽  
Anne Mwirigi ◽  
Susan Ward ◽  
Saad M.B. Rassam
Keyword(s):  
Multiple Myeloma ◽  
Renal Function ◽  
Stem Cell ◽  
Plasma Cell ◽  
Plasma Cells ◽  
Cell Leukaemia ◽  
First Line ◽  
Plasma Cell Disorders ◽  
Plasma Cell Leukaemia

Abstract Abstract 4963 Plasma cell leukemia [PCL] is the most aggressive form of plasma cell neoplasms constituting 2% to 4% of all cases of plasma cell disorders. The presentation may be primary or secondary from an existing multiple myeloma. Approximately 60 to 70% of cases are primary. Immunophenotype of PCL cells differs from the most of other myelomas with more frequent expression of CD20 antigen (50% vs. 17%), and lack CD56 antigen present on the majority of multiple myeloma cells. PCL patients have a higher presenting tumor burden with higher frequencies of anaemia, organomegaly, renal impairment, increased levels of serum lactate dehydrogenase (LDH), β-2 microglobulin and plasma cell proliferative activity. Prognosis of PCL is exceptionally poor with median survival of 6.8 months for patients with primary PCL and 1.3 months for patients with secondary PCL. It responds poorly to conventional myeloma treatment and polychemotherapy approach has yielded some short lived success. Recently, bortezomib has been reported first line in combination with other agents with good initial response. In the UK, bortezomib is not approved as a first line treatment for plasma cell disorders. The Hyper CVAD regimen (fractionated high dose cyclophosphamide and dexamethasone with infusional vincristine and adriamycin) has been developed for acute lymphoblastic leukaemia by the M D Anderson group and has also been shown to be effective in other aggressive B-cell disorders such as mantle cell and Burkitt's lymphoma. There are few single patient anecdotal reports of its efficacy in plasma cell leukaemia. We report three cases of plasma cell leukaemia successfully induced with limited courses of Hyper CVAD chemotherapy and long term remissions achieved with stem cell transplantation. Two men aged 53 and 56 and one woman aged 40 presented with PCL. All were anaemic (median Hb 8.5 g/dl), had impaired renal function, raised beta-2 microglobulin, creatinine, circulating plasma cells and plasmablasts and almost total marrow replacement by plasma cells. Two had IgG kappa paraprotein and one had light chains only. All had weak CD56 expression and two, where tested, were CD38 positive. Cytogenetic analysis was positive in one patient with t(4,14). All received hydration, bisphosphonate and allopurinol preparation before induction with the Hyper CVAD regimen. Two, given Thalidomide as well, achieved morphological complete remission (CR) after one course of therapy with marked reduction of paraprotein and normalisation of renal function. They received one further course of Hyper CVAD before receiving a Melphalan conditioned autlogous stem cell (ASCT) followed by a reduced intensity conditioning (RIC) sibling allogeneiec transplant in one patient. She remains in CR and full donor chimerism 11 months post SCT. The other is being prepared for ASCT to be followed by a RIC voluntary unrelated transplant. The patient with light chain disease achieved partial response (20% plasma cells in the bone marrow) after one course of Hyper CVAD without Thalidomide but a complete response after the second. He was consolidated with a third cycle, followed by a course of mini BEAM and then a RIC sibling allogeneic SCT. He had an early relapse 12 months following his SCT but responded to a course of donor lymphocyte infusion (DLI) and remains in CR 8.5 years from his SCT. Discussion To our knowledge, this is the largest series using this approach in PCL reported in the literature. PCL is a rare but aggressive disease with poor response to conventional therapy and short survival. Hyper CVAD appears to be highly effective in inducing a good response after 1-2 cycles of therapy particularly when combined with thalidomide. It appears that PCL is sensitive to the graft-versus-myeloma effect with long lasting remissions after allogeneic SCT and DLI therapy. Disclosures Rassam: Johnson and Johnson: Research Funding.

scholarly journals Lenalidomide, Melphalan, and Prednisone Association Is an Effective Salvage Therapy in Relapsed Plasma Cell Leukaemia

2009 ◽  
Vol 2009 ◽  
pp. 1-2 ◽  
Author(s):  
Tommasina Guglielmelli ◽  
Roberta Merlini ◽  
Emilia Giugliano ◽  
Giuseppe Saglio
Keyword(s):  
Plasma Cell ◽  
Salvage Therapy ◽  
Plasma Cells ◽  
Single Case ◽  
Case Reports ◽  
Cell Leukaemia ◽  
First Line Therapy ◽  
Plasma Cell Leukaemia ◽  
Plasma Cell Disorder ◽  
Cell Disorder

Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, characterized by the presence of a peripheral blood absolute plasma cell count of at least2×109/l and more than 20% circulating plasma cells. The prognosis of PCL patients remains poor. Even by using autologous or allogenic transplant procedures, median survival does not exceed 3 years (Saccaro et al., 2005). Thalidomide, bortezomib and lenalidomide (Revlimid) have emerged as high active agents in the treatment of PCL (Johnston and abdalla, 2002; Musto et al., 2007; Finnegan et al., 2006). In particular, Lenalidomide is a structural analogue of thalidomide with similar but more potent biological activity; it is used as first line therapy in MM (Palumbo et al., 2007; Niesvizky et al., 2007), although information regarding its associated use with dexamethasone use as salvage therapy in PCL derives from anecdotal single case reports (Musto et al., 2008). We would like to describe a case of primary PCL with adverse cytogenetic in which excellent response was achieved with the combination of lenalidomide, melphalan, and prednisone as salvage therapy.

Plasma cell leukaemia with t(11;14) not responsive to venetoclax

2021 ◽  
Vol 14 (1) ◽  
pp. e238641
Author(s):  
Mohammed Isaac Abu Zaanona ◽  
Priyank Patel
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cell ◽  
Plasma Cells ◽  
In Situ Hybridisation ◽  
Haematopoietic Stem Cell ◽  
Successful Outcome ◽  
Cell Leukaemia ◽  
Plasma Cell Leukaemia ◽  
History Of ◽  
Early Phase Clinical Trials

A 70-year-old man with medical history of IgG kappa multiple myeloma, initially diagnosed in 2017, underwent induction therapy with carfilzomib, lenalidomide and dexamethasone followed by autologous haematopoietic stem cell transplantation. Nine months following transplant, disease relapsed in the form of plasma cell leukaemia. Fluorescent in situ hybridisation of malignant plasma cells revealed t(11;14). A combination therapy including venetoclax was used based on efficacy data for Bcl-2 inhibitor venetoclax from available early-phase clinical trials in patients with relapsed multiple myeloma with t(11;14) and other published case studies. Unfortunately, the disease was primary refractory, and after further ineffective therapies, the patient did not have a successful outcome.

scholarly journals Primary Plasma Cell Leukaemia: Case report and review of the literature

2018 ◽  
Vol 18 (3) ◽  
pp. 397
Author(s):  
Sarika Singh ◽  
Ashutosh Rath ◽  
Surekha Yadav
Keyword(s):  
Case Report ◽  
Plasma Cell ◽  
Plasma Cells ◽  
Renal Involvement ◽  
Specific Treatment ◽  
Peripheral Blood Smear ◽  
Cell Leukaemia ◽  
Plasma Cell Dyscrasia ◽  
Diagnostic Features ◽  
Plasma Cell Leukaemia

Plasma cell leukaemia (PCL) is one of the most aggressive and rarest forms of plasma cell dyscrasia. However, the diagnostic criteria for this condition have not yet been revised and there is no specific treatment to significantly improve the course of the disease. We report a 69-year-old male who presented to the Lok Nayak Hospital, New Delhi, India, in 2017 with dyspnoea and chest pain. A peripheral blood smear showed an absolute plasma cell count of 2.16 × 109/L. A bone marrow examination showed 61% atypical plasma cells exhibiting kappa light chain restriction. Biochemical investigations were consistent with a diagnosis of primary PCL with renal involvement. Bortezomib-based chemotherapy was initiated, which resulted in an improvement in the patient’s haematological and biochemical parameters. This case report includes a comprehensive review of the clinical and diagnostic features, pathobiology and treatment of PCL.Keywords: Plasma Cell Leukemia; Multiple Myeloma; Plasma Cells; Case Report; India.

scholarly journals Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia

2012 ◽  
Vol 157 (4) ◽  
pp. 497-498 ◽  
Author(s):  
Alessandro Gozzetti ◽  
Pellegrino Musto ◽  
Marzia Defina ◽  
Fiorella D'Auria ◽  
Giulia Papini ◽  
...  
Keyword(s):  
Plasma Cell ◽  
Cell Leukaemia ◽  
Plasma Cell Leukaemia ◽  
Secondary Plasma
Sign in / Sign up

Export Citation Format

Share Document